A Systematic In Silico Search for Target Similarity Identifies Several Approved Drugs with Potential Activity against the Plasmodium falciparum Apicoplast

Most of the drugs in use against Plasmodium falciparum share similar modes of action and, consequently, there is a need to identify alternative potential drug targets. Here, we focus on the apicoplast, a malarial plastid-like organelle of algal source which evolved through secondary endosymbiosis. We undertake a systematic in silico target-based identification approach for detecting drugs already approved for clinical use in humans that may be able to interfere with the P. falciparum apicoplast. The P. falciparum genome database GeneDB was used to compile a list of ≈600 proteins containing apicoplast signal peptides. Each of these proteins was treated as a potential drug target and its predicted sequence was used to interrogate three different freely available databases (Therapeutic Target Database, DrugBank and STITCH3.1) that provide synoptic data on drugs and their primary or putative drug targets. We were able to identify several drugs that are expected to interact with forty-seven (47) peptides predicted to be involved in the biology of the P. falciparum apicoplast. Fifteen (15) of these putative targets are predicted to have affinity to drugs that are already approved for clinical use but have never been evaluated against malaria parasites. We suggest that some of these drugs should be experimentally tested and/or serve as leads for engineering new antimalarials.

[1]  Geoffrey I. McFadden,et al.  Plastid in human parasites , 1996, Nature.

[2]  Yang Song,et al.  Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery , 2011, Nucleic Acids Res..

[3]  W. Rees,et al.  Mechanisms of gastroduodenal protection by sucralfate. , 1991, The American journal of medicine.

[4]  L. Scheibel,et al.  Antimalarial activity of selected aromatic chelators. , 1980, Molecular pharmacology.

[5]  P. Prognon,et al.  Roles of divalent cations and pH in mechanism of action of nitroxoline against Escherichia coli strains , 1995, Antimicrobial agents and chemotherapy.

[6]  Amedeo Caflisch,et al.  Discovery of Plasmepsin Inhibitors by Fragment‐Based Docking and Consensus Scoring , 2009, ChemMedChem.

[7]  G. McFadden,et al.  Characterization of Two Malaria Parasite Organelle Translation Elongation Factor G Proteins: The Likely Targets of the Anti-Malarial Fusidic Acid , 2011, PloS one.

[8]  L. Scheibel,et al.  Antimalarial activity of selected aromatic chelators. II. Substituted quinolines and quinoline-N-oxides. , 1981, Molecular pharmacology.

[9]  S. L. Jensen,et al.  Role of sucralfate in peptic disease. , 1992, Digestive diseases.

[10]  O. Hoegh‐Guldberg,et al.  A photosynthetic alveolate closely related to apicomplexan parasites , 2008, Nature.

[11]  Jun O. Liu,et al.  Effect of nitroxoline on angiogenesis and growth of human bladder cancer. , 2010, Journal of the National Cancer Institute.

[12]  J. Wiesner,et al.  The plastid-like organelle of apicomplexan parasites as drug target. , 2008, Current pharmaceutical design.

[13]  C. J. Woodrow,et al.  Antimalarial drugs: recent advances in molecular determinants of resistance and their clinical significance , 2006, Cellular and Molecular Life Sciences CMLS.

[14]  R. Wilson,et al.  Malaria and other Apicomplexans: the "plant" connection. , 1994, Infectious agents and disease.

[15]  Christopher J. Tonkin,et al.  Tropical infectious diseases: Metabolic maps and functions of the Plasmodium falciparum apicoplast , 2004, Nature Reviews Microbiology.

[16]  A. Hickey,et al.  Isoxyl Aerosols for Tuberculosis Treatment: Preparation and Characterization of Particles , 2010, AAPS PharmSciTech.

[17]  Ramón García-Domenech,et al.  Identification of new antimalarial drugs by linear discriminant analysis and topological virtual screening. , 2006, The Journal of antimicrobial chemotherapy.

[18]  C. Muller-Serieys,et al.  [Present status of nitroxoline]. , 1987, Pathologie-biologie.

[19]  Damian Szklarczyk,et al.  STITCH 3: zooming in on protein–chemical interactions , 2011, Nucleic Acids Res..

[20]  A. Shonhai Plasmodial heat shock proteins: targets for chemotherapy. , 2010, FEMS immunology and medical microbiology.

[21]  J. Le bras,et al.  The mechanisms of resistance to antimalarial drugs in Plasmodium falciparum , 2003, Fundamental & clinical pharmacology.

[22]  David S. Wishart,et al.  DrugBank 3.0: a comprehensive resource for ‘Omics’ research on drugs , 2010, Nucleic Acids Res..

[23]  Y. Kitade,et al.  Molecular basis of fosmidomycin's action on the human malaria parasite Plasmodium falciparum , 2011, Scientific reports.

[24]  Organização Mundial de Saúde,et al.  World malaria report 2011 , 2011 .

[25]  G. McFadden,et al.  Plasmodium falciparum apicoplast drugs: targets or off-targets? , 2012, Chemical reviews.

[26]  H. Lichtenthaler,et al.  Inhibitors of the nonmevalonate pathway of isoprenoid biosynthesis as antimalarial drugs. , 1999, Science.

[27]  S. Archer Recent progress in the chemotherapy of schistosomiasis. , 1974, Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques.

[28]  Gurdyal S Besra,et al.  Unique Mechanism of Action of the Thiourea Drug Isoxyl on Mycobacterium tuberculosis* , 2003, Journal of Biological Chemistry.

[29]  J. D. Douglas,et al.  Antimycobacterial Activities of Isoxyl and New Derivatives through the Inhibition of Mycolic Acid Synthesis , 1999, Antimicrobial Agents and Chemotherapy.

[30]  Shekhar Kc Schistosomiasis Drug Therapy and Treatment Considerations , 1991 .

[31]  I. Galhaup Azelaic acid: mode of action at cellular and subcellular levels. , 1989, Acta dermato-venereologica. Supplementum.

[32]  K. Shekhar Schistosomiasis Drug Therapy and Treatment Considerations , 2012, Drugs.